Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present ITUS Corp. (NASDAQ: ITUS).

Full DD Report for ITUS

You must become a subscriber to view this report.


Recent News from (NASDAQ: ITUS)

ITUS Corporation to Present at the 3rd Annual Disruptive Growth & Healthcare Conference Hosted by RHK Capital and ReedSmith
NEW YORK, NY / ACCESSWIRE / May 1, 2018 / ITUS Corporation (NASDAQ: ITUS) announced today that it will be presenting at the 3 rd annual Disruptive Growth & Healthcare Conference on Tuesday, May 8 th at 10:45 AM EDT. Dr. Amit Kumar, President and CEO of ITUS Corporation, will be present...
Source: ACCESSWIRE
Date: May, 01 2018 07:00
ITUS Presentation to Special Meeting of Stockholders
SAN JOSE, Calif. , April 2, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that the presentation given by its Chief Executive Officer, Dr. Amit Kumar , at its Special Meeting of Stockholders on March 29, 2018 has been placed on the Company's website.  It can ...
Source: PR Newswire
Date: April, 02 2018 07:00
Wired News - ITUS Announces Results of a Blinded Prostate Cancer Study in Collaboration with Serametrix
Stock Monitor: AMREP Post Earnings Reporting LONDON, UK / ACCESSWIRE / March 29, 2018 / Active-Investors.com has just released a free research report on ITUS Corp. (NASDAQ: ITUS ). If you want access to this report all you need to do is sign up now by clicking the following link www...
Source: ACCESSWIRE IA
Date: March, 29 2018 07:40
ITUS and Serametrix Announce Results of a Blinded Prostate Cancer Study
SAN JOSE, Calif. , March, 27, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that it has completed a prostate cancer study with Serametrix in which data from a previous collaboration between Serametrix and Memorial Sloan Kettering Cancer Center (MSK) was re-evalua...
Source: PR Newswire
Date: March, 27 2018 07:00
ITUS Announces Issuance of Second Key Cancer Detection Technology Patent
SAN JOSE, Calif. , March 26, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS), a company using the power of the immune system to diagnose and treat cancer, today announced that the United States Patent and Trademark Office ("USPTO") has issued US Patent No. 9,934,364.  This is th...
Source: PR Newswire
Date: March, 26 2018 07:00
ITUS to Present Data from Early Cancer Detection Study Utilizing Artificial Intelligence at the American Association of Immunologists (AAI) Meeting
SAN JOSE, Calif. , March 16, 2018 /PRNewswire/ --   ITUS Corporation (NASDAQ: ITUS), today announced that it will present the latest data from its ongoing early cancer detection study at the annual meeting of the American Association of Immunologists (AAI) in Austin , Texas.  T...
Source: PR Newswire
Date: March, 16 2018 07:00
ITUS will Present Data at the American Association of Cancer Research (AACR) Annual Meeting
SAN JOSE, Calif. , March 12, 2018 /PRNewswire/ --   ITUS Corporation (NASDAQ: ITUS), today announced that it will present data from its ongoing study utilizing Cchek™, ITUS's artificial intelligence (AI) driven early cancer detection technology.  The presentation will be ...
Source: PR Newswire
Date: March, 12 2018 07:00
ITUS Corporation to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)
SAN JOSE, Calif. , March 9, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that John Roop , Senior Vice President of Engineering is scheduled to present on Friday March 16, 2018 , at 4:30 p.m. China Standard Time, 4:30 a.m. Eastern Standard Time , at the 2...
Source: PR Newswire
Date: March, 09 2018 07:00
Premarket Gainers as of 9:05 am (03/05/2018)
CLSD +66%  as Bio's suprachoroidal CLS-TA successful in late-stage uveitis study. More news on: Clearside Biomedical, XL Group plc, AXA ADR, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: March, 05 2018 09:16
ITUS Corporation Forms Alliance with Serametrix Corporation
SAN JOSE, Calif. , March 5, 2018 /PRNewswire/ -- ITUS Corporation (NASDAQ: ITUS) today announced that ITUS and Serametrix Corporation have signed an agreement to bring the power of Cchek™, ITUS's proprietary, AI-driven liquid biopsy cancer diagnostic technology to Serametrix's...
Source: PR Newswire
Date: March, 05 2018 07:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-05-183.453.60013.653.41165,637
2018-05-173.453.60013.653.41165,637
2018-02-263.503.353.503.30137,200
2018-02-233.353.363.473.217198,745
2018-02-223.233.333.36973.15251,506

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-13159,610263,86160.4902Short
2018-08-1024,11949,34048.8833Short
2018-08-0951,02558,88186.6578Short
2018-08-0810,81118,21059.3685Short
2018-08-0712,51930,23841.4015Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ITUS.


About ITUS Corp. (NASDAQ: ITUS)

Logo for ITUS Corp. (NASDAQ: ITUS)

ITUS funds, develops, acquires, and licenses emerging technologies. Our current areas of interest include High Tech., Biotechnology, Life Sciences, and Informatics. Current licensing programs involve encrypted communications, and advanced materials. ITUS has an ongoing program to develop highly efficient, flat panel displays, based upon a proprietary technology utilizing carbon Nanotubes and phosphor luminescence. Additional information is available at www.ITUScorp.com

 

Contact Information

 

 

Current Management

  • Robert A. Berman / CEO, President
  • Henry P. Herms / CFO
  • Dean Krouch / Manager, Ops., Corporate Secretary
  • Lewis Titterton / Chairman
  • Dr. Andrea Balz /
  • Robert A. Berman /
  • Dale Fox /
  • Bruce F Johnson /
  • Dr. Amit Kumar /

Current Share Structure

  • Market Cap: $74,341,424 - 03/21/2018
  • Issue and Outstanding: 16,631,191 - 03/05/2018

 


Recent Filings from (NASDAQ: ITUS)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 14 2018
Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock
Filing Type: 144Filing Source: edgar
Filing Date: April, 11 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 11 2018
Non-EDGAR filing submitted by "insiders" prior to intended sale of restricted stock
Filing Type: 144Filing Source: edgar
Filing Date: April, 11 2018
Amendment to a previously filed Form 4
Filing Type: 4/AFiling Source: edgar
Filing Date: April, 11 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 02 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 27 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: March, 27 2018

 

 


Daily Technical Chart for (NASDAQ: ITUS)

Daily Technical Chart for (NASDAQ: ITUS)


Stay tuned for daily updates and more on (NASDAQ: ITUS)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: ITUS)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ITUS is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of ITUS and does not buy, sell, or trade any shares of ITUS. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/